Tesaro doubles after niraparib shows survival benefit

Tesaro Inc. (NASDAQ:TSRO) soared $40.19 (108%) to $77.40 on Wednesday, adding $1.8 billion in market cap, after it said niraparib ( MK-4827) met the primary endpoint of improving progression-free survival (PFS) in the Phase III NOVA trial. The study evaluated niraparib

Read the full 417 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE